Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals

Launched by FRED HUTCHINSON CANCER CENTER · Feb 5, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a medication called remdesivir to see if it can effectively treat upper respiratory tract infections caused by the respiratory syncytial virus (RSV) in individuals with weakened immune systems. These patients often receive treatments for conditions like lymphoma or multiple myeloma, which can make them more vulnerable to infections. RSV is a common virus that can lead to serious respiratory problems, especially in people whose immune systems are not functioning well. The trial aims to find out if remdesivir, an antiviral drug that helps stop the spread of viruses in the body, can improve the health of these patients during RSV infections.

To be eligible for the trial, participants must be at least 18 years old and have a confirmed RSV infection, along with specific underlying health conditions or recent treatments that affect their immune system. They should also exhibit symptoms related to RSV. During the trial, participants will receive the study drug and undergo regular check-ups to monitor their health and response to the treatment. It’s important to note that this trial is not yet recruiting participants, so there will be more information available in the future for those interested in taking part.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged ≥ 18 years
• • Willing and able to provide written informed consent, or with a legal representative who can provide informed consent (where locally approved)
• • RSV confirmed by local lab testing via nucleic acid amplification test (e.g. polymerase chain reaction \[PCR\] or respiratory viral panel \[RVP\]) using an upper respiratory tract sample collected within the 5 days prior to day 1 (RDV dosing)
• • Symptomatic RSV infection of the upper respiratory tract, with symptom onset and positive microbiologic testing within the 5 days prior to day 1 (RDV dosing). Symptomatic RSV infection is defined as having new upper respiratory symptom(s) or worsening of a pre-existing upper respiratory symptom (if chronic and associated with a previously existing diagnosis, such as chronic lung disease, chronic rhinorrhea, or seasonal allergies)
• * Have one of the following underlying diseases and/or received one of the following treatments relative to RSV diagnosis date:
• • Received allogeneic hematopoietic cell transplant (HCT) with any conditioning regimen within 1 year
• • Received autologous HCT with any conditioning regimen within 3 months
• • Received Chimeric antigen receptor T cell therapy (CARTx) within 3 months
• • Have multiple myeloma (MM) and received bispecific antibody therapy (bsAb) within 3 months
• • Have lymphoma and received bsAb within 3 months
• * Categorized as moderate-risk (overall score 3-6) or high-risk (overall score 7-12) per an adapted version of the Immunodeficiency Scoring Index (ISI) for RSV, as below, relative to the day of RSV diagnosis:
• * 1 point:
• • Recent (within the prior 30 days) allogeneic HCT, autologous HCT, or CARTx
• • Corticosteroids within the prior 30 days for management of graft versus host disease (GVHD) or cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS).
• * 2 points:
• • Age ≥ 40 years
• * 3 points:
• • Absolute neutrophil count (ANC) \< 500 cells/μL within the prior 7 days
• • Absolute lymphocyte count (ALC) \< 200 cells/µL within the prior 7 days
• • Oxygen saturation (SpO2) 92% or greater on room air and at rest (to be measured after participant has rested in a quiet room for ≥ 2 minutes, with oxygen \[O2\] saturation probe on finger or earlobe for ≥ 1 minute, with saturation reading remaining ≥ 92%) at screening
• • Willingness to take study drug and complete necessary study procedures
• Exclusion Criteria:
• • Received or receiving an approved or authorized direct-acting antiviral therapy with potential efficacy against RSV (e.g. ribavirin) for ≥ 24 hours within the prior 7 days
• • Received or receiving investigational direct-acting antiviral therapies against RSV for the current RSV episode
• • Received any investigational monoclonal anti-RSV antibodies within \< 4 months or \< 5 half-lives, whichever is longer, before screening
• • Received an RSV vaccine after cellular therapy or after starting the current antitumor therapeutic regimen
• • Participation in any other concurrent clinical trial of an experimental treatment for RSV, including RSV vaccines
• • Alanine aminotransferase (ALT) \> 10 times the upper limit of normal within 7 days prior to screening
• • New lower respiratory tract radiographic abnormalities after RSV-associated symptom onset that are suspected to be due to RSV
• • Unable to tolerate nasal sampling required for this study, as determined by the investigator (e.g., history of significant epistaxis, nasopharyngeal anatomical abnormalities, nasal or sinus surgery)
• • A life expectancy of three months or less, as determined by the investigator
• • Pregnant, as determined by a Point-of-Care urine pregnancy test or reported by the patient or their electronic health record within 7 days of screening
• • Receiving, requiring, or expected to require supplemental oxygen for RSV-related illness or SpO2 \< 92% at rest \< 24 hours prior to study drug administration
• • Previous infection and/or hospitalization for RSV, or previous infection with, treatment for, or hospitalization for another respiratory viral infection within 28 days prior to screening
• • Documented positive test for other respiratory viruses concomitantly (limited to influenza, parainfluenza, adenovirus, human metapneumovirus, or coronavirus \[including SARS-CoV-2\]) ≤ 7 days prior to screening, as determined by local testing (additional testing not required)
• • Clinically significant bacteremia or fungemia ≤ 7 days prior to screening and not adequately treated, as determined by the investigator
• • Clinically significant bacterial, fungal, or viral pneumonia within two (2) weeks prior to screening and not adequately treated, as determined by the investigator
• • Clinically significant symptoms of CRS or ICANS within the prior 72 hours before screening that is not adequately controlled, as determined by the investigator
• • Any inability to take study drug or comply with study procedures that, in the opinion of the investigator, would make the participant unsuitable for the study
• • Known hypersensitivity or allergy to the study drug, its metabolites, or formulation excipients